Follow RSS for latest reports on this topicMultiple Myeloma - Market Research and Reports

Myeloma, also known as multiple myeloma, is a cancer arising from plasma cells, a type of white blood cell which is made in the bone marrow.  The bone marrow is where all blood cells are madeand is the ‘spongy’ material found in the centre of the larger bones in the body..

Plasma cells form part of your immune system by producing antibodies, also called immunoglobulins, to help fight infection.

In myeloma, these plasma cells become abnormal, multiply uncontrollably and release only one type of antibody – known as paraprotein – which has no useful function. The measurement of paraprotein is a key indicator that myeloma is diagnosed.

Unlike many cancers, myeloma does not exist as a lump or tumour. Most of the medical problems related to myeloma are caused by the build-up of the abnormal plasma cells in the bone marrow and the presence of the paraprotein in the blood or in the urine.

Myeloma affects multiple places in the body (hence ‘multiple’ myeloma) where bone marrow is normally active in an adult i.e. within the bones of the spine, skull, pelvis, the rib cage, long bones of the arms and legs and the areas around the shoulders and hips.

Myeloma is a relapsing-remitting cancer. This means there are periods when the myeloma is causing symptoms and/or complications and needs to be treated, followed by periods of remission or plateau where the myeloma does not cause symptoms and does not require treatment.

Adapted from - http://www.myeloma.org.uk/information/what-is-myeloma/

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found over 40 reports that matched your search.

Next 40 Matches >

Refine your search, and find more matches, using the form above.

Global Orphan Drugs Market by Disease Type (Oncologic Diseases, Metabolic Diseases, Hematologic and Immunologic Diseases, Infectious Diseases, Neurologic Diseases and Other Rare Diseases), Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma an [Report Updated: 24-04-2017]

The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for 6 billion in 2015, and is anticipated to reach 9 billion by 2022, registering a CAGR of 6.8% from 2016 to 2022.nnOrphan drugs are used to treat rare (orphaned) diseases prevalent in a very small patie...Read More >>>

Published:
2017-04-24

Published by: Allied Market Research

Prices Starting From:
$5370

Additional Searches

You may also like to search separately for: Multiple Myeloma

We Stock...

{STICKYFOOTERMOBILE}